Institution
University of Vermont
Education•Burlington, Vermont, United States•
About: University of Vermont is a education organization based out in Burlington, Vermont, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 17592 authors who have published 38251 publications receiving 1609874 citations. The organization is also known as: UVM & University of Vermont and State Agricultural College.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, the stability of solitons in parity-time (PT)-symmetric periodic potentials (optical lattices) is analyzed in both one-and two-dimensional systems.
Abstract: Stability of solitons in parity-time (PT)-symmetric periodic potentials (optical lattices) is analyzed in both one- and two-dimensional systems First we show analytically that when the strength of the gain-loss component in the PT lattice rises above a certain threshold (phase transition point), an infinite number of linear Bloch bands turn complex simultaneously Second, we show that while stable families of solitons can exist in PT lattices, increasing the gain-loss component has an overall destabilizing effect on soliton propagation Specifically, when the gain-loss component increases, the parameter range of stable solitons shrinks as new regions of instability appear Third, we investigate the nonlinear evolution of unstable PT solitons under perturbations, and show that the energy of perturbed solitons can grow unbounded even though the PT lattice is below the phase transition point
286 citations
••
TL;DR: Sutton et al. as discussed by the authors investigated the contributions of four basic types of capital (human, social, built, and natural) to life satisfaction and proposed a National Well-Being Index (NWI) based on their findings.
286 citations
••
TL;DR: This review highlights recent targeted approaches towards improving microbial tolerance to next-generation biofuels with a particular emphasis on strategies that will improve production.
Abstract: A major challenge when using microorganisms to produce bulk chemicals such as biofuels is that the production targets are often toxic to cells. Many biofuels are known to reduce cell viability through damage to the cell membrane and interference with essential physiological processes. Therefore, cells must trade off biofuel production and survival, reducing potential yields. Recently, there have been several efforts towards engineering strains for biofuel tolerance. Promising methods include engineering biofuel export systems, heat shock proteins, membrane modifications, more general stress responses, and approaches that integrate multiple tolerance strategies. In addition, in situ recovery methods and media supplements can help to ease the burden of end-product toxicity and may be used in combination with genetic approaches. Recent advances in systems and synthetic biology provide a framework for tolerance engineering. This review highlights recent targeted approaches towards improving microbial tolerance to next-generation biofuels with a particular emphasis on strategies that will improve production.
286 citations
••
TL;DR: In patients with CAD, normal weight with central obesity is associated with the highest risk of mortality [corrected].
286 citations
••
TL;DR: Treatment algorithms are presented to help guide the management of patients with CDI, including a toxin-binding polymer, tolevamer; 2 poorly absorbed antimicrobials, OPT-80 and ramoplanin; monoclonal antibodies; and a C. difficile vaccine.
Abstract: Recent outbreaks of Clostridium difficile infection (CDI) in North America have been due to a more virulent, possibly more resistant strain that causes more-severe disease, making prompt recognition of cases and optimal management of infection essential for a successful therapeutic outcome. Treatment algorithms are presented to help guide the management of patients with CDI. Metronidazole has been recommended as initial therapy since the late 1990s and continues to be the first choice for all but seriously ill patients and those with complicated or fulminant infections or multiple recurrences of CDI, for whom vancomycin is recommended. Other options for recurrent CDI, such as probiotics and currently available anion-exchange resins, have limited efficacy and are potentially harmful. Intravenous immunoglobulin may benefit patients with refractory, recurrent, or severe disease, but no controlled data are available. Two antimicrobials available in the United States for other indications, nitazoxanide and rifaximin, have been used successfully for CDI treatment but, like metronidazole, lack United States Food and Drug Administration approval for this indication. Experimental treatments currently in clinical development include a toxin-binding polymer, tolevamer; 2 poorly absorbed antimicrobials, OPT-80 (formerly known as Difimicin) and ramoplanin; monoclonal antibodies; and a C. difficile vaccine.
285 citations
Authors
Showing all 17727 results
Name | H-index | Papers | Citations |
---|---|---|---|
Albert Hofman | 267 | 2530 | 321405 |
Ralph B. D'Agostino | 226 | 1287 | 229636 |
George Davey Smith | 224 | 2540 | 248373 |
Stephen V. Faraone | 188 | 1427 | 140298 |
Valentin Fuster | 179 | 1462 | 185164 |
Dennis J. Selkoe | 177 | 607 | 145825 |
Anders Björklund | 165 | 769 | 84268 |
Alfred L. Goldberg | 156 | 474 | 88296 |
Christopher P. Cannon | 151 | 1118 | 108906 |
Debbie A Lawlor | 147 | 1114 | 101123 |
Roger J. Davis | 147 | 498 | 103478 |
Andrew S. Levey | 144 | 600 | 156845 |
Jonathan G. Seidman | 137 | 563 | 89782 |
Yu Huang | 136 | 1492 | 89209 |
Christine E. Seidman | 134 | 519 | 67895 |